Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI). Objectives: To evaluate the in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborb...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-12-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221008092 |
| _version_ | 1818460158235246592 |
|---|---|
| author | Helio S. Sader Mariana Castanheira Leonard R. Duncan Rodrigo E. Mendes |
| author_facet | Helio S. Sader Mariana Castanheira Leonard R. Duncan Rodrigo E. Mendes |
| author_sort | Helio S. Sader |
| collection | DOAJ |
| description | Background: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI). Objectives: To evaluate the in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from patients hospitalized with skin and soft tissue infections (SSTIs) in several countries around the world. Methods: A total of 360 P. aeruginosa isolates were consecutively collected from 47 medical centers located in Western Europe, Eastern Europe, the Asia-Pacific region, and Latin America. Susceptibility testing was performed by broth microdilution method at a monitoring laboratory. EUCAST breakpoints were applied. Results: Ceftazidime/avibactam (98.3% susceptible), ceftolozane/tazobactam (98.6% susceptible), and imipenem/relebactam (98.3% susceptible) were the most active compounds after colistin (100.0% susceptible) and retained activity against isolates nonsusceptible to piperacillin/tazobactam, meropenem, imipenem, and/or ceftazidime. Meropenem-vaborbactam was active against 94.2% of isolates. Ceftazidime/avibactam was the most active BL/BLI against meropenem-nonsusceptible (92.6% susceptible) and imipenem-resistant (93.8% susceptible) isolates, whereas ceftolozane/tazobactam was the most active BL/BLI against piperacillin/tazobactam-resistant (91.1% susceptible) and ceftazidime-resistant (91.7% susceptible) isolates. Conclusions: The recently approved BL/BLIs demonstrated potent activity and broad coverage against contemporary P. aeruginosa isolates from patients with SSTIs. |
| first_indexed | 2024-12-14T23:25:48Z |
| format | Article |
| id | doaj.art-bf9c27dc44894de6a4e64077bcd0288a |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-14T23:25:48Z |
| publishDate | 2021-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-bf9c27dc44894de6a4e64077bcd0288a2022-12-21T22:43:48ZengElsevierInternational Journal of Infectious Diseases1201-97122021-12-01113279281Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infectionsHelio S. Sader0Mariana Castanheira1Leonard R. Duncan2Rodrigo E. Mendes3Corresponding author: Helio S. Sader, MD, PhD, FIDSA, JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, Phone: (319) 665-3370; Fax: (319) 665-3371.; JMI Laboratories, North Liberty, Iowa, USAJMI Laboratories, North Liberty, Iowa, USAJMI Laboratories, North Liberty, Iowa, USAJMI Laboratories, North Liberty, Iowa, USABackground: The limited armamentarium against multidrug-resistant Gram-negative bacilli led to the development of a new generation of β-lactam/β-lactamase inhibitor combinations (BL/BLI). Objectives: To evaluate the in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, and imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from patients hospitalized with skin and soft tissue infections (SSTIs) in several countries around the world. Methods: A total of 360 P. aeruginosa isolates were consecutively collected from 47 medical centers located in Western Europe, Eastern Europe, the Asia-Pacific region, and Latin America. Susceptibility testing was performed by broth microdilution method at a monitoring laboratory. EUCAST breakpoints were applied. Results: Ceftazidime/avibactam (98.3% susceptible), ceftolozane/tazobactam (98.6% susceptible), and imipenem/relebactam (98.3% susceptible) were the most active compounds after colistin (100.0% susceptible) and retained activity against isolates nonsusceptible to piperacillin/tazobactam, meropenem, imipenem, and/or ceftazidime. Meropenem-vaborbactam was active against 94.2% of isolates. Ceftazidime/avibactam was the most active BL/BLI against meropenem-nonsusceptible (92.6% susceptible) and imipenem-resistant (93.8% susceptible) isolates, whereas ceftolozane/tazobactam was the most active BL/BLI against piperacillin/tazobactam-resistant (91.1% susceptible) and ceftazidime-resistant (91.7% susceptible) isolates. Conclusions: The recently approved BL/BLIs demonstrated potent activity and broad coverage against contemporary P. aeruginosa isolates from patients with SSTIs.http://www.sciencedirect.com/science/article/pii/S1201971221008092Pseudomonas aeruginosaceftazidime/avibactamceftolozane/tazobactamimipenem/relebactammeropenem/vaborbactam |
| spellingShingle | Helio S. Sader Mariana Castanheira Leonard R. Duncan Rodrigo E. Mendes Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections International Journal of Infectious Diseases Pseudomonas aeruginosa ceftazidime/avibactam ceftolozane/tazobactam imipenem/relebactam meropenem/vaborbactam |
| title | Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections |
| title_full | Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections |
| title_fullStr | Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections |
| title_full_unstemmed | Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections |
| title_short | Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections |
| title_sort | antimicrobial activities of ceftazidime avibactam ceftolozane tazobactam imipenem relebactam meropenem vaborbactam and comparators against pseudomonas aeruginosa from patients with skin and soft tissue infections |
| topic | Pseudomonas aeruginosa ceftazidime/avibactam ceftolozane/tazobactam imipenem/relebactam meropenem/vaborbactam |
| url | http://www.sciencedirect.com/science/article/pii/S1201971221008092 |
| work_keys_str_mv | AT heliossader antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamimipenemrelebactammeropenemvaborbactamandcomparatorsagainstpseudomonasaeruginosafrompatientswithskinandsofttissueinfections AT marianacastanheira antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamimipenemrelebactammeropenemvaborbactamandcomparatorsagainstpseudomonasaeruginosafrompatientswithskinandsofttissueinfections AT leonardrduncan antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamimipenemrelebactammeropenemvaborbactamandcomparatorsagainstpseudomonasaeruginosafrompatientswithskinandsofttissueinfections AT rodrigoemendes antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamimipenemrelebactammeropenemvaborbactamandcomparatorsagainstpseudomonasaeruginosafrompatientswithskinandsofttissueinfections |